Clinicopathologic characteristics and diagnostic value of PD-L1 in immune checkpoint inhibitor-related liver injury: a single-center retrospective study.
- 1Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
- 2Liver Research Center, Beijing Friendship Hospital, Capital Medical University & National Clinical Research Center for Digestive Diseases, Beijing, China.
- 3Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Abstract
Background and aims
Immune-mediated liver injury caused by checkpoint inhibitors (ILICI) differs from chemotherapy- or targeted drug-related hepatotoxicity in pathogenesis and management. Biomarkers to distinguish ILICI from other anticancer agent-induced liver injuries are lacking. We compared the clinicopathological features, treatments, and outcomes of ILICI versus other anticancer agent-related liver injuries to identify distinguishing biomarkers.Methods
We retrospectively included patients with liver injury during anticancer therapy at Fujian Cancer Hospital between June 2022 and November 2024. Cases were classified as ILICI or non-ILICI using the Common Terminology Criteria for Adverse Events v5.0 and the Roussel Uclaf Causality Assessment Method.Results
Sixty-seven patients were enrolled, including 30 ILICI and 37 non-ILICI. ILICI was associated with more high-grade liver injury than non-ILICI (P = 0.001), with similar latency, recovery time, and prognosis. Corticosteroids were administered in 70% of ILICI vs. 5.4% of non-ILICI patients (P < 0.001). Among 29 liver biopsies (19 ILICI, 10 non-ILICI), ILICI showed a higher focal necrosis score (P = 0.031) and programmed death-ligand 1 (PD-L1) expression in liver sinusoidal endothelial cells (LSECs), lymphocytes, and Kupffer cells (KCs) (P = 0.007). Receiver operating characteristic analysis showed that a PD-L1 positivity cutoff of >30% in LSECs, lymphocytes, and KCs discriminated ILICI with an AUC of 0.811 (95%CI: 0.641-0.980). Sensitivity analyses and Firth penalized logistic regression confirmed that this finding remained robust after adjustment for confounders including pre-biopsy corticosteroid use and inactive HBV carrier status.Conclusions
ILICI was associated with more severe hepatic inflammatory necrosis and a greater need for immunosuppressive therapy than non-ILICI. The PD-L1 positivity rate >30% in LSECs, lymphocytes, and KCs may serve as a potential diagnostic biomarker for ILICI.
Related
- Clinical characteristics and prognosis of liver injury in patients receiving immune checkpoint inhibitor-based therapy: a real-world retrospective study
- Immune Checkpoint Inhibitor-Related Hepatitis Versus Classical Autoimmune Hepatitis: A Retrospective Multidomain Phenotype Comparison
- Safety of concurrent immune checkpoint inhibitor therapy during postoperative radiotherapy for triple-negative breast cancer: A preliminary retrospective analysis
- Integrated multi-omics identifies distinct immune signatures with diagnostic and therapeutic implications in immune checkpoint inhibitor-induced myocarditis
- Clinical characteristics and pharmacovigilance signals of immune checkpoint inhibitor-associated cystitis and ureteritis: analysis of FAERS reports and published cases
BibTeX
@article{lai2026clinicopathologic,
title = {{Clinicopathologic characteristics and diagnostic value of PD-L1 in immune checkpoint inhibitor-related liver injury: a single-center retrospective study.}},
author = {Huaying Lai and Xinyan Zhao and Dongmei Zhou and Luping Lin and Jianwei Zhang and Yu Chen and Sha Huang},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1928835},
url = {https://europepmc.org/article/MED/42908539},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinicopathologic characteristics and diagnostic value of PD-L1 in immune checkpoint inhibitor-related liver injury: a single-center retrospective study.
AU - Huaying Lai
AU - Xinyan Zhao
AU - Dongmei Zhou
AU - Luping Lin
AU - Jianwei Zhang
AU - Yu Chen
AU - Sha Huang
PY - 2026
DA - 2026/10/07
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1928835
UR - https://europepmc.org/article/MED/42908539
AB - Background and aims Immune-mediated liver injury caused by checkpoint inhibitors (ILICI) differs from chemotherapy- or targeted drug-related hepatotoxicity in pathogenesis and management. Biomarkers to distinguish ILICI from other anticancer agent-induced liver injuries are lacking. We compared the clinicopathological features, treatments, and outcomes of ILICI versus other anticancer agent-related liver injuries to identify distinguishing biomarkers.Methods We retrospectively included patients with liver injury during anticancer therapy at Fujian Cancer Hospital between June 2022 and November 2024. Cases were classified as ILICI or non-ILICI using the Common Terminology Criteria for Adverse Events v5.0 and the Roussel Uclaf Causality Assessment Method.Results Sixty-seven patients were enrolled, including 30 ILICI and 37 non-ILICI. ILICI was associated with more high-grade liver injury than non-ILICI (P = 0.001), with similar latency, recovery time, and prognosis. Corticosteroids were administered in 70% of ILICI vs. 5.4% of non-ILICI patients (P < 0.001). Among 29 liver biopsies (19 ILICI, 10 non-ILICI), ILICI showed a higher focal necrosis score (P = 0.031) and programmed death-ligand 1 (PD-L1) expression in liver sinusoidal endothelial cells (LSECs), lymphocytes, and Kupffer cells (KCs) (P = 0.007). Receiver operating characteristic analysis showed that a PD-L1 positivity cutoff of >30% in LSECs, lymphocytes, and KCs discriminated ILICI with an AUC of 0.811 (95%CI: 0.641-0.980). Sensitivity analyses and Firth penalized logistic regression confirmed that this finding remained robust after adjustment for confounders including pre-biopsy corticosteroid use and inactive HBV carrier status.Conclusions ILICI was associated with more severe hepatic inflammatory necrosis and a greater need for immunosuppressive therapy than non-ILICI. The PD-L1 positivity rate >30% in LSECs, lymphocytes, and KCs may serve as a potential diagnostic biomarker for ILICI.
SN - 2234-943X
ER -